Intensive glucose control in type 2 diabetes patients can increase mortality risk, study finds

The common approach of intensive glucose control to achieve low blood sugar targets in type 2 diabetes can increase the risk of mortality, finds a study by Cardiff University.

Looking at routine data from over 300,000 people in the UK, collected between 2004 and 2015, researchers found that lower levels of glycated hemoglobin--typically regarded as being good diabetes control - were associated with increased mortality risk, compared to moderate levels, especially in conjunction with intensive treatments that could cause hypoglycemia.

Professor Craig Currie from Cardiff University's School of Medicine said: "Treatment guidelines generally recommend therapeutic strategies that aim for low levels of glucose control, on the understanding that it reduces risk of macrovascular complications such as coronary artery disease and stroke. Contrary to this belief, our findings show persuasively that there is an association with increased mortality risk and what is considered to be good glucose control, or low HbA1c."

The findings of the study also suggest that neither randomised trials nor observational studies have been able to demonstrate a consistent pattern of association between levels of glucose control and adverse outcome, without any explanation as to why. Thus, the optimal target for glucose control in patients with type 2 diabetes remains uncertain. Furthermore, the pattern of mortality in relation to glucose control differed in relation to differing types of diabetes drugs. Of most concern was an increase in mortality risk in those with 'good control' with type 2 diabetes who were treated with insulin and other glucose lowering drugs that induce hypoglycemia.

Professor Currie said: "Serious questions remain about the safety of some glucose lowering drugs, with scientific evidence and opposing opinions being largely ignored."

Source: http://www.cardiff.ac.uk/news/view/1004909-good-glucose-could-be-bad-in-type-2-diabetes

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Rare variant analysis reveals genetic spectrum of monogenic diabetes genes